BlackRock
CADL icon

BlackRock’s Candel Therapeutics CADL Stock Holding History

BlackRock’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$51.2M Buy
4,969,040
+1,859,998
+60% +$14.1M ﹤0.01% 2660
2026
Q1 		$15.2M Buy
3,109,042
+247,353
+9% +$1.35M ﹤0.01% 3239
2025
Q4 		$16.2M Buy
2,861,689
+482,359
+20% +$2.59M ﹤0.01% 3202
2025
Q3 		$12.1M Buy
2,379,330
+77,485
+3% +$448K ﹤0.01% 3351
2025
Q2 		$11.6M Buy
2,301,845
+538,075
+31% +$2.77M ﹤0.01% 3336
2025
Q1 		$9.97M Buy
1,763,770
+579,823
+49% +$4.74M ﹤0.01% 3327
2024
Q4 		$10.3M Buy
1,183,947
+58,268
+5% +$344K ﹤0.01% 3416
2024
Q3 		$7.8M Buy
1,125,679
+302,608
+37% +$1.88M ﹤0.01% 3532
2024
Q2 		$5.1M Buy
823,071
+775,491
+1,630% +$5.82M ﹤0.01% 3675
2024
Q1 		$75.2K Sell
47,580
-1,705
-3% -$2.53K ﹤0.01% 4796
2023
Q4 		$72.5K Sell
49,285
-564
-1% -$548 ﹤0.01% 4891
2023
Q3 		$45.9K Sell
49,849
-1,974
-4% -$2.28K ﹤0.01% 5021
2023
Q2 		$65.3K Buy
51,823
+5,279
+11% +$7.8K ﹤0.01% 5020
2023
Q1 		$62.8K Buy
46,544
+7,497
+19% +$14.6K ﹤0.01% 5073
2022
Q4 		$69.9K Sell
39,047
-85,923
-69% -$170K ﹤0.01% 5144
2022
Q3 		$393K Sell
124,970
-4,407
-3% -$14.9K ﹤0.01% 4795
2022
Q2 		$420K Sell
129,377
-2,945
-2% -$11.8K ﹤0.01% 4829
2022
Q1 		$674K Buy
132,322
+17,708
+15% +$87.9K ﹤0.01% 4791
2021
Q4 		$896K Buy
114,614
+92,288
+413% +$896K ﹤0.01% 4699
2021
Q3 		$242K Buy
+22,326
New +$185K ﹤0.01% 4940

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $2.67B AUM 169.09% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $617M AUM 69.99% 1-Year Est. Return

BlackRock's CADL Position: Q2 2026 in Review

BlackRock increased its Candel Therapeutics (CADL) stake by 60% in Q2 2026, buying an estimated $14.1M and bringing the position to 4,969,040 shares worth $51.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2660.

BlackRock first reported a position in CADL in Q3 2021 and has held it in 20 quarters since. 138 funds tracked by Wall St. Rank hold CADL as of Q2 2026.

  • BlackRock held 4,969,040 shares of Candel Therapeutics worth $51.2M as of Q2 2026.
  • BlackRock bought 1,859,998 Candel Therapeutics shares in Q2 2026, an estimated $14.1M.
  • Candel Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2660 holding.
  • BlackRock first reported a position in Candel Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • 138 funds tracked by Wall St. Rank held Candel Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.